Continuing Education Activity

Opioid antagonists act by competitively binding to opioid receptors in the central and peripheral nervous systems without activating them, effectively blocking the effects of opioid agonists. These agents, including naloxone, naltrexone, methylnaltrexone, and nalmefene, target mu (μ), kappa (κ), and delta (δ) receptors to reverse opioid effects, manage opioid and alcohol use disorders, and alleviate opioid-induced constipation. This course reviews opioid antagonists, focusing on their pharmacology, clinical applications, administration protocols, and safety considerations. Participants will gain insight into the mechanisms of key agents like naloxone, naltrexone, and methylnaltrexone, and their vital roles in reversing opioid overdose, managing opioid use disorder, and mitigating opioid-induced adverse effects. Advances in molecular pharmacology that inform the design of next-generation antagonists with improved safety and efficacy are also discussed. Peripherally acting μ-opioid receptor antagonists (PAMORAs) have also been discussed for the treatment of opioid induced constipation.

This course explores precipitated withdrawal, adverse effects, and current federal policies impacting opioid addiction treatment, as well as the selection of appropriate antagonists, optimizing dosing and monitoring strategies, and implementation of patient-centered protocols to prevent overdose and manage withdrawal safely. Community naloxone distribution efforts, legislative protections, and the implications of the Mainstreaming Addiction Treatment Act, which broadens access to buprenorphine for opioid use disorder treatment, are also emphasized. This activity for healthcare professionals is designed to enhance the learner's competence in integrating opioid antagonists into clinical management, adhering to current opioid guidelines, and implementing an appropriate interprofessional approach in patients receiving opioid antagonist therapy to address the opioid crisis effectively, improve patient safety, and reduce overdose mortality.

Objectives:

• Evaluate the mechanisms of action for various opioid antagonists.
• Apply evidence-based guidelines for the implementation of opioid antagonist therapy.
• Select appropriate opioid antagonists based on clinical indication.
• Collaborate with interprofessional healthcare team members to coordinate opioid overdose prevention strategies utilizing opioid antagonists.

Indications

Opioid antagonists function by binding to opioid receptors in the central and peripheral nervous systems without activating them, thus blocking the effects of opioid agonists. The primary opioid receptors involved are the mu (μ), kappa (κ), and delta (δ) receptors, all G protein-coupled receptors. Opioid agonists typically inhibit adenylate cyclase activity via the Gi protein, reducing intracellular cyclic AMP (cAMP) and neurotransmitter release, leading to analgesia, respiratory depression, and euphoria. Opioid antagonists competitively inhibit these receptors, preventing agonist binding and subsequent intracellular signaling.[1]

Recent molecular insights reveal that opioid receptor antagonism may involve complex receptor-G protein interactions beyond simple competitive inhibition. For example, certain κ-opioid receptor inverse agonists can bind to receptor-G protein complexes in inactive conformations, illustrating nuanced mechanisms of receptor blockade. Following agonist binding, opioid receptors undergo phosphorylation and β-arrestin recruitment, leading to receptor desensitization and internalization. Antagonists can modulate this process by preventing receptor activation and downstream signaling, maintaining receptor availability, or modulating basal receptor activity, "receptor desensitization and internalization" mechanisms.[2] 

Clinically important opioid antagonists include:

• Naloxone: quickly reverses opioid overdose by blocking central μ receptors
• Naltrexone: used for maintenance treatment of opioid and alcohol use disorders
• Nalmefene: offers longer action and is used for overdose reversal and alcohol use disorder treatment in some regions [3] 
• Peripherally acting μ-opioid receptor antagonists (PAMORAs): Indicated for opioid-induced constipation [4]

  • Methylnaltrexone
  • Naloxegol
  • Naldemedine

The FDA has approved the prefilled naloxone (Zimhi). In May 2023, the USFDA approved the nalmefene nasal spray (Opvee) for the emergency management of known or suspected opioid overdose in adults and pediatrics 12 years of age and older.[5] In 2024, the USFDA also approved the nalmefene autoinjector (Zurnai).[6] Currently, 3 PAMORAs (methylnaltrexone, naloxegol, and naldemedine) are approved for the treatment ofopioid-inducedd constipation. They are especially effective in laxative-refractory constipation. The American Gastroenterological Association (AGA) endorses the use of PAMORA for opioid-induced constipation; however, it remains underutilized.[4][7]

A 2025 meta-analysis showed that opioid antagonists may reduce binge eating frequency and body weight loss in affected patients, supporting research into expanding their therapeutic indications beyond substance use disorders.[8] This nuanced understanding of opioid receptor signaling and antagonism is critical for developing improved treatments aimed at managing opioid use disorder, overdose prevention, and adverse effect mitigation, eg, constipation or respiratory depression. Advances in molecular pharmacology understanding also support ongoing research into next-generation antagonists with better pharmacological profiles.[3] 

Opioid Antagonists and Risk Mitigation Strategies

Enhancing healthcare outcomes in opioid antagonist therapy involves adhering to guidelines, eg, the 2022 Centers for Disease Control (CDC) Guideline for Prescribing Opioids for Chronic Pain.[9] This guideline recommends risk mitigation strategies, including prescribing naloxone to patients with a history of substance use disorder, those at high overdose risk, patients on high opioid doses (>50 morphine mg equivalents daily), individuals recently released from incarceration at risk of returning to high opioid doses, and patients concurrently using benzodiazepines. Such strategies aim to reduce opioid-related adverse events, including overdose and mortality.

Community distribution and prescription of naloxone have demonstrated a dose-dependent relative risk reduction in opioid overdose mortality. This has influenced legislative actions to provide legal protections for bystanders who administer naloxone or activate emergency services during an overdose event.

The Mainstreaming Addiction Treatment (MAT) Act, effective as of December 2022, expanded access by allowing all Drug Enforcement Administration (DEA)-registered practitioners with Schedule III authority to prescribe buprenorphine for opioid use disorder without special Drug Addiction Treatment Act (DATA) waiver certification. This change removes patient limits and streamlines prescription and dispensing processes. The MAT Act facilitates integration of substance use disorder treatment across healthcare settings, reducing stigma and improving access to evidence-based medications like buprenorphine.[10] The Medication Access and Training Expansion (MATE) Act requires all DEA prescribers to complete training on Substance Use Disorders (SUDs).[11]

This updated framework, aligned with CDC 2022 guidelines and federal legislation, improves healthcare outcomes by promoting harm reduction, expanding access to treatment, and reinforcing coordinated interprofessional care.[9] A 2025 systematic review and meta-analysis found that both buprenorphine-naloxone (BUP-NX) and extended-release naltrexone (XR-NTX) are comparably effective for opioid use disorder in terms of abstinence duration, with XR-NTX reducing opioid use days slightly more. Both treatments have similar safety profiles, underscoring the need for individualized treatment selection based on patient-specific factors.[12]

Recent clinical research demonstrates that nalmefene, administered through a new autoinjector device (ZURNAI) as described above, produces a faster onset and a longer duration of action in reversing fentanyl-induced respiratory depression when compared to standard intranasal naloxone. This pharmacokinetic advantage makes nalmefene a promising alternative for out-of-hospital opioid overdose situations, particularly in scenarios involving synthetic opioids with extended half-lives, eg, fentanyl and its analogs. These findings highlight nalmefene's potential to improve patient outcomes by sustaining opioid reversal and reducing the risk of renarcotization after severe exposures.[13]

Mechanism of Action

Centrally acting opioid receptor antagonists, eg, naloxone and naltrexone, function primarily as potent competitive inhibitors with the highest affinity for the μ opioid receptor. By competitively binding to these central receptors without activating them, they reverse the effects of opioid agonists like respiratory depression, analgesia, euphoria, and sedation. Naloxone is commonly used in acute opioid overdose emergencies to stimulate respiratory drive, increase alertness, terminate analgesia and euphoria, and cause pupil dilation (mydriasis). Naltrexone, meanwhile, is used mainly for maintenance therapy in opioid and alcohol use disorders by reducing cravings through sustained μ receptor antagonism. The longer half-life of nalmefene and higher binding affinity to opioid receptors make nalmefene a more effective agent than naloxone in the reversal of high-potency synthetic opioids like fentanyl; however, withdrawal can be severe.

Peripherally acting opioid receptor antagonists, including methylnaltrexone and similar drugs, do not readily cross the blood-brain barrier, so their antagonistic effects are confined to peripheral μ receptors found in high concentrations in bronchial smooth muscle and the digestive tract. These antagonists competitively inhibit peripheral μ receptors to alleviate opioid-induced adverse effects, eg, constipation by promoting intestinal hypermotility. Notably, peripheral μ receptors contribute substantially to analgesia; some studies estimate that they account for about 60%, suggesting that antagonizing peripheral receptors may reduce analgesic efficacy or precipitate acute pain episodes.[14]

At the molecular level, opioid receptors are G protein-coupled receptors that, when activated by an opioid agonist, inhibit adenylate cyclase activity via Gi/o proteins, reducing intracellular cyclic AMP (cAMP). This signaling cascade leads to decreased neurotransmitter release and hyperpolarization of neurons via potassium channel activation, clinically producing analgesia and other opioid effects. Antagonists competitively bind these receptors, preventing agonist binding and subsequent intracellular signaling. Additionally, receptor activation triggers phosphorylation and recruitment of β-arrestin proteins, which mediate receptor desensitization and internalization. Antagonists block receptor activation, thus inhibiting these downstream processes and rapidly reversing opioid effects.[15]

In brief, opioid antagonists work by competitively binding opioid receptors, chiefly the μ receptor, to block the effects of opioid agonists in the central nervous system or peripheral tissues, depending on their ability to cross the blood-brain barrier. This mechanism underlies their clinical use in opioid overdose reversal, maintenance therapy for opioid use disorder, and treatment of opioid-induced constipation.

Administration

Available Dosage Forms

Various forms of opioid antagonist administration include oral, intranasal, intravenous (IV), intramuscular (IM), subcutaneous (SC), sublingual, and buccal. The details are given in the table below. The primary difference in route of administration among common peripherally acting μ-opioid receptor antagonists (PAMORAs) is that naloxegol and naldemedine are oral formulations, whereas methylnaltrexone is available as both an oral tablet and a subcutaneous injection. Naloxegol and naldemedine offer convenient administration for the management of opioid-induced constipation (see Table. Opioid Antagonist Formulations).[16][17]

Available Strengths and Ad ult Dosage

These administration considerations highlight the importance of carefully managing antagonist initiation to minimize adverse effects and ensure patient safety during opioid withdrawal treatment. Various forms of administration include oral, intranasal, IV, IM, SC, sublingual, and buccal. Product-specific uses are summarized in the table given below. The following is a list of opioid antagonist classifications and recommended doses, along with the route of administration for general reference. Individual assessment of each patient is required. Clinical decision-making must be tailored to specific patient presentations, comorbidities, medications, and institutional protocols. Consult current guidelines, institutional standards, and interprofessional team input before clinical implementation. Critical reassessment of individual patients is required at every stage of care.

Table

Table. Opioid Antagonist Formulations.

Recommendations

Administration of opioid antagonists, eg, naloxone and naltrexone, can precipitate acute opioid withdrawal, especially if given to individuals with physical opioid dependence. This precipitated withdrawal can occur in prehospital or emergency settings with naloxone or during medically supervised withdrawal protocols with either naloxone or naltrexone. Symptoms may be severe enough to require hospital admission or intensive care management. Though rare, there have been isolated case reports of stress-induced cardiomyopathy and organic delusional disorder linked to precipitated withdrawal episodes. More commonly, patients experience significant nausea, vomiting, and diarrhea necessitating intravenous hydration and electrolyte replacement to maintain stability.[18] 

The extended half-life of nalmefene and its higher affinity for opioid receptors render it a more effective agent than naloxone for reversing high-potency synthetic opioids such as fentanyl. However, the American College of Medical Toxicology and the American Academy of Clinical Toxicology recommend that, due to limited research on intranasal nalmefene in synthetic opioid overdoses and its potential to cause harm through prolonged withdrawal, it should not replace naloxone as the primary opioid antidote. Further studies are needed.[19] However, case reports indicate promising results in opioid overdose.[20]

During medically supervised withdrawal treatments, naltrexone dosing is typically introduced gradually over 3 to 7 days to allow an opioid "washout," minimizing sudden withdrawal symptoms. This naltrexone-accelerated withdrawal carries a high risk of complications and generally requires adjunctive treatment with alpha-2 adrenergic agonists, eg, clonidine or lofexidine, to alleviate autonomic symptoms.[21] Lofexidine is preferred because it causes less hypotension than alternatives.[21] Additionally, symptomatic comfort medications, eg, benzodiazepines (for anxiety and agitation), antiemetics (for nausea), and muscle relaxants, are routinely used to manage withdrawal-related discomfort. Benzodiazepines should be utilized with extreme caution with opioids due to the risk of severe respiratory depression.[9]

According to CDC guidelines, naltrexone should be administered via monthly, long-acting injections. The effectiveness of oral naltrexone may be limited by poor adherence, and it should be used only in specific circumstances for patients capable of complying with daily dosing under observation to improve adherence.[9]

Specific Patient Populations

Hepatic impairment

Management of pruritus is a concern in chronic liver disease. An increase in opioidergic tone has been marked in patients with cholestatic pruritus. Naltrexone is typically started at doses from 12.5 mg up to 150 mg daily. In clinical studies, oral naltrexone and nalmefene, as well as intravenous naloxone, have shown significant reductions in pruritus severity compared to placebo. A study also demonstrated notable improvements in pruritus scores with naltrexone. Many patients experienced substantial relief, with some reporting complete resolution. 

The adverse effect profile in cholestatic patients was predominantly mild and transient, requiring no additional treatment, though a few patients discontinued due to severe opioid withdrawal effects. Naltrexone generally demonstrated a safer profile compared to nalmefene, with fewer severe adverse events.[22] Buprenorphine/naloxone is not recommended in severe hepatic impairment; use with caution in moderate hepatic impairment.[23]

Renal impairment

Pain management in chronic kidney disease should be tailored to the individual. NSAIDs should be avoided in advanced chronic kidney disease (CKD). Use of opioids must be very carefully considered; however, a link between opioid dose and mortality in dialysis patients has been noted. Higher rates of dialysis discontinuation, hospitalization, and death have been observed in patients prescribed opioids.[24] Acetaminophen and topical NSAIDs can be helpful.

Pain should be categorized by etiology, and a multimodal approach with a pain management specialist is recommended. For Nalexgol, dose reduction is required in severe renal impairment (CrCl <60 mL/min). Similarly, dose reduction is needed for methylnaltrexone. In an emergency opioid overdose, naloxone can be administered at the initial dose of 0.4 mg to 2 mg IV, and repeated at 2 to 3 minute intervals.[25][24] If required, buprenorphine can be prescribed with caution.[25] The dose of naloxegol for patients with a CrCl <60 mL/min should be reduced to 12.5 mg once daily.

Pregnancy considerations

According to the American College of Obstetricians and Gynecologists (ACOG), naloxone can be life-saving in the setting of opioid overdose during pregnancy. ACOG acknowledges that although rapid opioid withdrawal can lead to fetal stress, naloxone should be administered to pregnant patients in the case of maternal opioid overdose to preserve maternal life. Naloxone may be administered intravenously or subcutaneously by health care or emergency medical personnel, and autoinjector and prepackaged nasal spray formulations may be given by family members or other bystanders when opioid overdose is suspected.[26]

Breastfeeding considerations

Naloxone appears in breast milk in minimal amounts and is not detectable in infants' plasma due to its poor oral bioavailability. Routine use in combination products is generally safe during breastfeeding. However, if naloxone is needed for an opioid overdose, mothers should pause nursing until the drug clears their system.[27]

Pediatric patients

The American Academy of Pediatrics 2024 guidelines recommend co-prescribing naloxone with opioids for pediatric patients. Codeine/tramadol should be avoided in patients younger than 12 years of age. Caregivers should be educated on recognizing overdose symptoms and proper medication storage. Additionally, the guidelines outline potential harms associated with discontinuing or rapidly tapering opioids in pediatric patients who have been on stable, long-term opioid therapy for chronic pain.[28]

Older patients

The American Geriatric Society Beers criteria advise avoiding opioids except in the setting of severe acute pain. Benzodiazepines and opioid concurrent administration should be avoided. Opioids can induce delirium in geriatric patients. For older adults with pain, use a balanced approach, multimodal strategies that include nonpharmacological approaches to minimize opioid use.[29]

Adverse Effects

Accelerated protocols for naltrexone-assisted opioid withdrawal aim to shorten the time required for transition to naltrexone maintenance, reduce inpatient stay duration, and lower treatment costs. Limited clinical adoption results from potential complications associated with these approaches. The protocols often incorporate a "naloxone challenge," which begins with a very low intravenous dosage of 0.1 mg and gradually increases to 0.4 mg over approximately 1 hour to assess a patient's readiness for full naltrexone dosing without triggering withdrawal symptoms.

Extended-release injectable naltrexone (Vivitrol) has gained widespread use due to its 4-week dosing interval, which enhances adherence and convenience. During buprenorphine-naloxone induction, patients must enter mild-to-moderate withdrawal, typically reflected by a Clinical Opioid Withdrawal Scale score greater than 10 to 12, to benefit from buprenorphine's partial agonist effect and prevent precipitated withdrawal. The buprenorphine-naloxone formulation minimizes misuse because naloxone exhibits poor oral bioavailability yet induces withdrawal if injected intravenously.

PAMORAs, eg, naloxegol and naldemedine, can lead to gastrointestinal adverse effects like diarrhea, abdominal pain, and vomiting.[17][30] Adjunctive medications provide essential symptom relief during withdrawal management. Alpha-2 adrenergic agonists (eg, clonidine and lofexidine) reduce autonomic hyperactivity, with lofexidine carrying a lower risk of hypotension. Benzodiazepines mitigate anxiety and agitation, antiemetics control nausea and vomiting, and muscle relaxants alleviate musculoskeletal pain.

Effective induction and maintenance depend on individualized dosing strategies for opioid antagonists and supportive medications, guided by each patient's opioid use history and withdrawal severity, to minimize precipitated withdrawal and improve treatment outcomes.[31]  As per product labeling, hepatitis and hepatotoxicity have been described with naltrexone ER. Discontinue use of naltrexone ER in the event of hepatotoxicity. Recent studies indicate no major concern for hepatotoxicity; further research is required.[32][33]

Drug-Drug Interactions

Drug-drug interactions are associated with the following agents:

• Naloxone: Buprenorphine may require higher naloxone doses for reversal due to its strong, slow-dissociating affinity for μ-receptors. Naloxone is incompatible with preparations containing metabisulfite/bisulfite or IV solutions with alkaline pH. Methohexital can block naloxone-induced withdrawal symptoms in patients with opioid use disorder.

• Naltrexone: Naltrexone can precipitate severe withdrawal in opioid-dependent patients; do not administer until an opioid-free interval of 7 to 14 days is confirmed. Concomitant disulfiram may cause additive hepatotoxicity. For the extended-release injection (Vivitrol), use only the provided diluent; it is physically incompatible with other liquids, and the suspension must be administered immediately after reconstitution.

• Nalmefene: Nalmefene has a longer half-life (approximately 11 hours) than naloxone; however, buprenorphine-induced respiratory depression may still require higher or repeated doses for complete reversal.

• Buprenorphine/Naloxone: Use with benzodiazepines or other CNS depressants carries a warning for fatal respiratory depression.[34] CYP3A4 inhibitors (such as ketoconazole) increase buprenorphine plasma levels, while CYP3A4 inducers (such as rifampin) may decrease levels and precipitate withdrawal. 

• Methylnaltrexone: Concomitant use with other opioid antagonists may result in additive effects and the precipitation of systemic opioid withdrawal. In general, methylnaltrexone does not reverse centrally mediated analgesia or precipitate withdrawal.[35] Hypothetically, when the blood-brain barrier is compromised, withdrawal may be possible.

• Naloxegol: Strong CYP3A4 inducers, eg, rifampin, decrease naloxegol concentrations; concomitant use is not recommended.[36] Moderate CYP3A4 inhibitors, eg, diltiazem and verapamil, can increase naloxegol concentrations; avoid concomitant use; if unavoidable, reduce the dose to 12.5 mg once daily. Other opioid antagonists can have a potential for an additive effect and increased risk of opioid withdrawal; concomitant use should be avoided.

• Naldemedin: Strong CYP3A4 inducers, eg, rifampin, phenytoin, carbamazepine, and St. John's Wort, significantly decrease naldemedine levels by approximately and should be avoided. P-glycoprotein inhibitors, eg, cyclosporine, amiodarone, and quinidine, may increase concentrations of naldemedin. Clinicians should monitor for gastrointestinal complications.[37]

Contraindications

Naloxone, naltrexone, and nalmefene, buprenorphine/naloxone, and nalmefene nasal formulation are contraindicated in patients with a history of severe hypersensitivity reactions. Interestingly, the use of naloxone has been documented in an anaphylactoid reaction induced by hydromorphone.[38]

Naltrexone is contraindicated in patients who are currently dependent on opioids or are receiving opioid analgesics, as antagonism can precipitate severe withdrawal symptoms. Naloxone is FDA-approved for opioid overdose reversal via intravenous, intramuscular, and intranasal routes and is generally safe and effective in emergency use. Naltrexone is available in oral and long-acting injectable forms, mainly used for maintenance treatment of opioid and alcohol use disorders after patients have completed detoxification to avoid precipitated withdrawal.

A key contraindication is the risk of precipitated opioid withdrawal if these antagonists are administered before opioid clearance or detoxification, which can lead to hospitalization or intensive care admission. Patients must be opioid-free or in sufficient withdrawal before starting naltrexone to minimize this risk. Studies indicate that increased naloxone distribution in communities correlates with a dose-dependent reduction in opioid-related overdose mortality, reflecting the importance and relative safety of naloxone when correctly administered.[39]

Respiratory depression resulting from partial opioid agonists or mixed agonist–antagonists (eg, buprenorphine, pentazocine) may be only partially reversed by naloxone and may necessitate higher or repeated doses.

In summary, contraindications include ongoing opioid dependence, recent opioid use, and the need for opioid analgesics, where using antagonists could cause harm. Proper patient evaluation and timing of administration are crucial to avoid adverse effects from premature antagonist use. Naltrexone should not be administered to patients who have failed the naloxone challenge test.[40]

PAMORAs, eg, methylnaltrexone, naloxegol, and naldemedine, are contraindicated in known or suspected mechanical gastrointestinal obstruction and in patients with increased risk of recurrent obstruction.[41]

Naloxone Challenge Test

Because no method can fully confirm an adequate opioid-free interval, a naloxone challenge test may be used when occult opioid dependence is suspected before starting naltrexone. Do not perform the naloxone challenge test in patients with clinical opioid withdrawal or a urine drug screen positive for opioids. The naloxone challenge test may be administered through IV or SC routes.

The IV naloxone challenge involves the following protocol:

• Administer naloxone 0.2 mg IV.
• Observe for 30 seconds for signs or symptoms of withdrawal.
• If no withdrawal is observed, administer naloxone hydrochloride 0.6 mg IV (total 0.8 mg).
• Observe for an additional 20 minutes.

The SC naloxone challenge involves the following protocol:

• Administer naloxone hydrochloride 0.8 mg SC.
• Observe for 20 minutes for signs or symptoms of withdrawal.

Clinicians should note that opioid-dependent patients may respond to lower doses; naloxone hydrochloride 0.1 mg IV can be diagnostic. The naloxone challenge test may be helpful; however, several case reports have documented instances where patients experienced precipitated withdrawal despite negative urine toxicology screens or tolerating the test, often during the transition from buprenorphine therapy.

Interpretation

Clinicians should monitor vital signs and assess for opioid withdrawal, including nausea, abdominal cramps, rhinorrhea, yawning, lacrimation, piloerection, myalgias, anxiety, irritability, craving, and autonomic changes. Based on the following signs and symptoms, the test may be interpreted as positive or negative:

• Positive test: Any withdrawal signs or symptoms. Stop naloxone; not initiating naltrexone is advised. Repeat the challenge in 24 hours.
• Negative test: No withdrawal signs or symptoms are noted. Naltrexone may be initiated if no other contraindications are present.

Monitoring

Monitoring during opioid antagonist administration is critical to ensure patient safety and efficacy of treatment, especially in the context of opioid overdose reversal and medically supervised withdrawal.

Key Monitoring Parameters

Factors that should be monitored to determine the efficacy of treatment following opioid antagonist administration include:

• Respiratory status: Continuous monitoring of respiratory rate and oxygen saturation is essential, particularly after naloxone administration for opioid overdose reversal, to promptly detect and manage respiratory depression or recurrence. Arterial blood gas analysis should be obtained, and the acid-base disorder should be corrected. Patients may have progressive hypoventilation due to CNS depression in opioid overdose. Hypercapnic respiratory failure may occur in severe overdose.[42] Severe cases may require intubation and mechanical ventilation. Opioid-induced respiratory depression is the primary concern; synthetic opioids combined with coingestants, eg, Xylazine, are associated with high mortality, requiring high-dose naloxone despite clinical concerns about precipitated withdrawal or pulmonary edema. Xylazine-induced sedation is naloxone-refractory and requires intensive supportive care, as the drug's presence complicates the reversal of respiratory depression.
• Capnograph: In an overdose of opioids, continuous capnography with end-tidal carbon dioxide monitoring (ETCO₂) is beneficial.[43] Capnography helps guide naloxone administration and subsequent monitoring. Normalization of the capnography waveform and ETCO₂ reading can indicate improving ventilation, prompting the clinician to consider withholding further naloxone doses. Because some opioids persist longer in the body than naloxone, which has a half-life of 30 to 90 minutes, continuous monitoring with capnography and pulse oximetry is necessary for several hours. Capnography can provide a quantitative evaluation of ventilation and reveal ventilation changes more quickly than pulse oximetry.[44]
• Cardiovascular monitoring: Heart rate and blood pressure should be regularly assessed, as precipitated withdrawal can cause tachycardia, hypertension, or rare complications like stress-induced cardiomyopathy. (takotsubo cardiomyopathy).[45]
• Withdrawal symptoms: Patients must be closely observed for signs of opioid withdrawal, especially during naltrexone induction or naloxone challenge tests. Use of validated scales such as the COWS (Clinical Opiate Withdrawal Scale) helps quantify severity and guide supportive care.[18][46]
• Neurological status: Alertness, level of consciousness, and pupil size (mydriasis) should be monitored as indicators of antagonist effect and potential opioid intoxication or withdrawal. 
• Fluid and electrolyte balance: Because of common withdrawal symptoms, eg, vomiting and diarrhea, monitoring hydration status and electrolyte levels is essential for timely correction.
• Adverse reactions: Clinicians should watch for rare but serious adverse effects, eg, delirium or cardiac events, particularly in high-risk or medically complex patients.

Monitoring Settings

Emergency overdose reversal requires monitoring within prehospital or emergency department environments, where continuous assessment of vital signs guides rapid clinical response. Furthermore, during medically supervised withdrawal and naltrexone induction, patients benefit most from inpatient or structured outpatient settings that provide consistent clinical evaluations and comprehensive supportive care. Regular observation during this phase enables clinicians to detect early complications and adjust therapy as needed.

Ongoing monitoring facilitates timely intervention with supportive medications, including intravenous fluids, antiemetics, alpha-2 adrenergic agonists, or benzodiazepines. Prompt management of withdrawal-related symptoms enhances patient safety, promotes stabilization, and improves overall treatment outcomes.[47] The iatrogenic opioid withdrawal syndrome can occur due to improper cessation of opioids; avoid abrupt discontinuation.[48][49]

Prescription drug monitoring program (PDMP) should be utilized to identify opioid use disorder, cumulative dosing received, and if the patient has received simultaneous prescription of benzodiazepines with opioids, which can increase the risk of respiratory and CNS depression.[50] Physicians and other healthcare practitioners should not label patients receiving opioids for reasonable causes (eg, cancer pain) with reduced life expectancy as opioid abusers.[51]

Toxicity

Naloxone has minimal toxicity in individuals not exposed to opioids, exhibiting very few adverse effects in such cases. However, in opioid-dependent individuals, naloxone and other antagonists can precipitate abrupt opioid withdrawal syndrome characterized by agitation, nausea, vomiting, tachycardia, hypertension, and rarely severe complications, eg, cardiac events or delirium. Noncardiogenic pulmonary edema is a serious but rare complication that can occur after the administration of naloxone to reverse an opioid overdose. Naloxone should be administered to treat opioid overdoses while monitoring for the development of pulmonary edema. Noncardiogenic pulmonary edema has also been described as a complication of fentanyl intoxication, so determining the etiology is essential. Airway protection and intubation may be required.[52][53][54][55] 

Opioid-induced respiratory depression is the primary concern; synthetic opioids combined with coingestants, eg,  Xylazine, are associated with high mortality, requiring high-dose naloxone despite clinical concerns about precipitated withdrawal or pulmonary edema. Xylazine-induced sedation is naloxone-refractory and requires intensive supportive care, as the drug's presence complicates the reversal of respiratory depression.[56]

Additionally, gastrointestinal perforation cases have been reported with PAMORA. Postmarketing data include fatal cases in patients at risk, eg, those with gastrointestinal malignancies, diverticular disease, recent surgery, ischemic colitis, or bevacizumab use. The risks and benefits should be weighed carefully, especially in patients with compromised gastrointestinal wall integrity, eg, Crohn’s disease. Monitor for severe or worsening abdominal pain and discontinue naloxegol if it occurs.[41] Immediately consult the critical care team, gastroenterologist, and the surgery team if perforation is suspected.

Enhancing Healthcare Team Outcomes

Opioid-induced respiratory depression is a leading cause of preventable mortality in the United States, contributing to approximately 80,000 deaths annually and representing a major public health crisis.[56][57] Opioid antagonist therapies, including naloxone for overdose reversal and naltrexone—particularly long-acting injectable formulations—for relapse prevention, are central to reducing morbidity and mortality in opioid use disorder. These agents are especially valuable in patients with coexisting alcohol use disorder.[58] Safe and effective use requires careful withdrawal management, appropriate patient selection, gradual induction, and structured monitoring to avoid complications such as precipitated withdrawal, cardiopulmonary events, or rare adverse outcomes. Professional societies caution against ultra-rapid detoxification protocols because of increased risks without proven benefit.[59]

Optimizing outcomes with opioid antagonist therapy depends on coordinated interprofessional care. Physicians, general practitioners, and advanced practitioners guide evidence-based induction, maintenance, and monitoring strategies, while recognizing high-risk populations and contraindications. Nurses provide continuous assessment, patient education, and supportive care during withdrawal and maintenance. Pharmacists ensure appropriate dosing, identify drug interactions, and support adherence, particularly with long-acting formulations. Addiction medicine, psychiatry, critical care, and specialty consultants are essential in complex cases, including polysubstance use or severe withdrawal.[59] Clear handoffs, shared decision-making, and integration of social support services—augmented by privacy-conscious tools such as EHR-embedded AI screening—enhance patient safety, reduce readmissions, and promote sustained recovery through team-based, patient-centered care.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Lambert DG. Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis. BJA Open. 2023 Jun;6:100141. [PMC free article: PMC10430815] [PubMed: 37588171]

2.

Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018 Dec;43(13):2514-2520. [PMC free article: PMC6224460] [PubMed: 30250308]

3.

Green M, Veltri CA, Grundmann O. Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder. Subst Abuse Rehabil. 2024;15:43-57. [PMC free article: PMC10999209] [PubMed: 38585160]

4.

Portincasa P, Luglio CV, Sozzi S, Conforti C, Bitonto G, Papavero M, Baffy G, Di Ciaula A. Opioid-induced constipation in internal medicine: recognition and management pathways. Intern Emerg Med. 2025 Sep;20(6):1695-1704. [PMC free article: PMC12476432] [PubMed: 40877716]

5.

Nallani SC, Li Z, Florian J, Xu Y, Sabarinath S, Brescia-Oddo T, Roca RA, Uppoor RS, Mehta MU. FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose. Clin Pharmacol Ther. 2025 Mar;117(3):620-626. [PubMed: 39648641]

6.

Cipriano A, He E, Shet M, Apseloff G, Harris SC. Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto-Injector Versus Intranasal Naloxone. J Clin Pharmacol. 2025 Dec;65(12):1661-1675. [PMC free article: PMC12649286] [PubMed: 40796531]

7.

Liu K, Chen A, Rajaram P, Buning G, Lee AA, Singh P. PAMORAs in Opioid-Induced Constipation: Are We Following the Guidelines? Clin Transl Gastroenterol. 2025 Aug 01;16(8):e00876. [PMC free article: PMC12377320] [PubMed: 40512185]

8.

Fang YY, Yeh YC, Liu TL, Tien-Wei H, Ko CH. Efficacy of opioid antagonist in patients with binge eating behavior: A systemic review and meta-analysis. Neurosci Biobehav Rev. 2025 May;172:106108. [PubMed: 40096901]

9.

Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 04;71(3):1-95. [PMC free article: PMC9639433] [PubMed: 36327391]

10.

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015 Sep-Oct;9(5):358-67. [PMC free article: PMC4605275] [PubMed: 26406300]

11.

Morford KL, Tetrault JM, Fiellin DA. The MATE Act: Progress for substance use education, but is checking a box enough? J Gen Intern Med. 2024 Jun;39(8):1496-1498. [PMC free article: PMC11169132] [PubMed: 38308156]

12.

Awaji BH, Abanmi SN, Alqahtani MS, Alhodathi L, Alrehaili M, Aldohan TF, Alkhenaizan AS, Alsughayer ZM, Alyahya AA, Alanazi RMS, Aljohani H, Hassan Awaji HH, Alsuliman SY. Evaluating Treatment Options for Opiate Use Disorder: A Meta-Analysis of Buprenorphine-Naloxone and Extended-Release Naltrexone. Cureus. 2025 Aug;17(8):e89769. [PMC free article: PMC12421290] [PubMed: 40937222]

13.

Cipriano A, Apseloff G, Kapil RP, He E, Shet M, Harris SC. Time Course of Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone. J Clin Pharmacol. 2025 Feb;65(2):206-216. [PMC free article: PMC11771590] [PubMed: 39347921]

14.

Greenwood-Van Meerveld B, Standifer KM. Methylnaltrexone in the treatment of opioid-induced constipation. Clin Exp Gastroenterol. 2008;1:49-58. [PMC free article: PMC3108626] [PubMed: 21677823]

15.

Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011 Dec;115(6):1363-81. [PMC free article: PMC3698859] [PubMed: 22020140]

16.

Braun UK, Jackson LK, Garcia MA, Imam SN. A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients. Pharmacy (Basel). 2024 Mar 06;12(2) [PMC free article: PMC10961755] [PubMed: 38525728]

17.

Wobbe B, Gerner M, Köhne CH. Safety of Naldemedine for Opioid-Induced Constipation - A Systematic Review and Meta-Analysis. J Pain Palliat Care Pharmacother. 2025 Mar;39(1):96-113. [PubMed: 39699576]

18.

Dunn KE, Bird HE, Bergeria CL, Ware OD, Strain EC, Huhn AS. Operational definition of precipitated opioid withdrawal. Front Psychiatry. 2023;14:1141980. [PMC free article: PMC10162012] [PubMed: 37151972]

19.

Stolbach AI, Mazer-Amirshahi ME, Nelson LS, Cole JB. American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time. Clin Toxicol (Phila). 2023 Nov;61(11):952-955. [PubMed: 38039052]

20.

Sucher M, Emmans L. Opioid Overdose Reversal With Nalmefene Nasal Spray: A Case Report. Cureus. 2025 Jun;17(6):e85912. [PMC free article: PMC12164525] [PubMed: 40520837]

21.

Kuszmaul AK, Palmer EC, Frederick EK. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review. J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):145-152. [PubMed: 31791720]

22.

Marenco-Flores A, Sierra L, Goyes D, Kahan T, Patwardhan VR, Bonder A. Managing pruritus in chronic liver disease: An in-depth narrative review. Clin Liver Dis (Hoboken). 2024 Jan-Jun;23(1):e0187. [PMC free article: PMC11168844] [PubMed: 38872783]

23.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Nov 24, 2020. Buprenorphine. [PubMed: 31644178]

24.

Pellegrino B, Schmidt RJ. Pain Management in Patients With Kidney Disease-Patients Deserve a Prescriber With Specialty Expertise: KDOQI Controversies Series. Kidney Med. 2021 Jan-Feb;3(1):9-11. [PMC free article: PMC7873821] [PubMed: 33605942]

25.

Coluzzi F, Caputi FF, Billeci D, Pastore AL, Candeletti S, Rocco M, Romualdi P. Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists. Ther Clin Risk Manag. 2020;16:821-837. [PMC free article: PMC7490082] [PubMed: 32982255]

26.

Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017 Aug;130(2):e81-e94. [PubMed: 28742676]

27.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Feb 15, 2024. Naloxone. [PubMed: 30000741]

28.

Hadland SE, Agarwal R, Raman SR, Smith MJ, Bryl A, Michel J, Kelley-Quon LI, Raval MV, Renny MH, Larson-Steckler B, Wexelblatt S, Wilder RT, Flinn SK. Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline. Pediatrics. 2024 Sep 30; [PubMed: 39344439]

29.

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PMC free article: PMC12478568] [PubMed: 37139824]

30.

Gudin J, Fudin J. Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions. J Pain Res. 2020;13:447-456. [PMC free article: PMC7049282] [PubMed: 32158255]

31.

Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. [PMC free article: PMC4331107] [PubMed: 22404717]

32.

Díaz LA, Collier S, Yin J, Loomba R. Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease. Aliment Pharmacol Ther. 2025 Oct;62(7):692-698. [PMC free article: PMC12704194] [PubMed: 40515940]

33.

Qu W, Wang X, Dong C, Zhang T, Yin S, Sun Z, Wang S, Guo A, Hao W. Evaluating the antagonist effect of naltrexone implant via opioid challenge tests with escalating doses of hydromorphone injection in former heroin dependent patients. Front Psychiatry. 2025;16:1441598. [PMC free article: PMC11821577] [PubMed: 39950179]

34.

Carry E, Vasilatis A, Johnson AL, Ryan JW. Expecting medication misuse: a proactive approach to drug discovery to prevent fatal overdose. Future Med Chem. 2025 Mar;17(6):681-692. [PMC free article: PMC11938974] [PubMed: 40091621]

35.

Sawh SB, Selvaraj IP, Danga A, Cotton AL, Moss J, Patel PB. Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients. Mayo Clin Proc. 2012 Mar;87(3):255-9. [PMC free article: PMC3498420] [PubMed: 22386181]

36.

Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. J Clin Pharmacol. 2016 Aug;56(8):1019-27. [PubMed: 26678015]

37.

Fukumura K, Kawaguchi N, Ishibashi T, Kubota R, Tada Y, Ogura E. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects. Clin Drug Investig. 2020 Jun;40(6):529-540. [PMC free article: PMC7242238] [PubMed: 32323104]

38.

Mushlin N, Vahid B, Roberts R. Use of naloxone in hydromorphone-induced anaphylactoid reaction. South Med J. 2007 Jun;100(6):611. [PubMed: 17591317]

39.

Fischer LS, Asher A, Stein R, Becasen J, Doreson A, Mermin J, Meltzer MI, Edlin BR. Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis. BMC Public Health. 2025 Mar 25;25(1):1135. [PMC free article: PMC11934755] [PubMed: 40133970]

40.

Beauregard ER, Maguire EG. Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications. Ment Health Clin. 2024 Apr;14(2):102-106. [PMC free article: PMC11058323] [PubMed: 38694885]

41.

Mehta N, Laitman AP, Brookfield RB, Harris LA. Treatment of Opioid-Induced Constipation: Inducing Laxation and Understanding the Risk of Gastrointestinal Perforation. J Clin Gastroenterol. 2025 Jul 01;59(6):491-496. [PMC free article: PMC12165528] [PubMed: 40434810]

42.

Chung Y, Garden FL, Marks GB, Vedam H. Causes of hypercapnic respiratory failure and associated in-hospital mortality. Respirology. 2023 Feb;28(2):176-182. [PMC free article: PMC10092076] [PubMed: 36210347]

43.

Dolinak D. Opioid Toxicity. Acad Forensic Pathol. 2017 Mar;7(1):19-35. [PMC free article: PMC6474471] [PubMed: 31239953]

44.

Schwartz ZL, Routman JS. Sedation and Analgesia for the Interventional Radiologist. Semin Intervent Radiol. 2023 Apr;40(2):240-246. [PMC free article: PMC10275663] [PubMed: 37333735]

45.

Gartenberg A, Mathew T, Blyakher M, Chertoff A. Takotsubo cardiomyopathy induced by opioid withdrawal: a case report. CJEM. 2026 Feb;28(2):162-165. [PubMed: 40944869]

46.

Gregory C, Yadav K, Linders J, Sikora L, Eagles D. Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review. Addiction. 2025 Jan;120(1):7-20. [PubMed: 39322991]

47.

Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD002024. [PubMed: 19370574]

48.

Moisa E, Tuculeanu G, Corneci D, Negoita SI, Bilotta F. Iatrogenic withdrawal syndrome in adult intensive care unit: a scoping review. Front Med (Lausanne). 2025;12:1573363. [PMC free article: PMC12325356] [PubMed: 40771468]

49.

Lamey PS, Landis DM, Nugent KM. Iatrogenic opioid withdrawal syndromes in adults in intensive care units: a narrative review. J Thorac Dis. 2022 Jun;14(6):2297-2308. [PMC free article: PMC9264079] [PubMed: 35813766]

50.

Abraham AJ, Steuart SR, Lawler EC, Shone H, Adams GB. Concurrent Prescription Fills of Opioids and Benzodiazepines Among Postpartum Women During COVID-19. AJPM Focus. 2024 Aug;3(4):100251. [PMC free article: PMC11279250] [PubMed: 39070137]

51.

Trullols M, Ruiz de Porras V. Opioid Use in Cancer Pain Management: Navigating the Line Between Relief and Addiction. Int J Mol Sci. 2025 Aug 01;26(15) [PMC free article: PMC12347026] [PubMed: 40806585]

52.

Farkas A, Lynch MJ, Westover R, Giles J, Siripong N, Nalatwad A, Pizon AF, Martin-Gill C. Pulmonary Complications of Opioid Overdose Treated With Naloxone. Ann Emerg Med. 2020 Jan;75(1):39-48. [PubMed: 31182316]

53.

Marsalisi C, Guo HJ, Reddy P. The Double-Edged Sword: Naloxone-Induced Noncardiogenic Pulmonary Edema. Cureus. 2023 Jul;15(7):e41642. [PMC free article: PMC10412747] [PubMed: 37575849]

54.

Joseph M, Amin K, Siddens C, Jaime G, Seeger CM, Mercer K, Chau T. Pulmonary edema after naloxone administration for opioid reversal: a systematic review of case reports and causality assessment using the Naranjo scale. Clin Toxicol (Phila). 2024 May;62(5):334-342. [PubMed: 38865087]

55.

Jiwa N, Sheth H, Silverman R. Naloxone-Induced Non-Cardiogenic Pulmonary Edema: A Case Report. Drug Saf Case Rep. 2018 May 10;5(1):20. [PMC free article: PMC5945567] [PubMed: 29749582]

56.

Dahan A, Franko TS, Carroll JW, Craig DS, Crow C, Galinkin JL, Garrity JC, Peterson J, Rausch DB. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Front Public Health. 2024;12:1346109. [PMC free article: PMC10933112] [PubMed: 38481848]

57.

Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Rep. 2024 Jul;6(7):101095. [PMC free article: PMC11220533] [PubMed: 38961852]

58.

Hernandez Bustamante P, Charles A, Snider M, Catanzano S. Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review. Ment Health Clin. 2025 Feb;15(1):17-24. [PMC free article: PMC11835365] [PubMed: 39974754]

59.

The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91. [PubMed: 32511106]

Disclosure: Jonathan Theriot declares no relevant financial relationships with ineligible companies.

Disclosure: Sarah Sabir declares no relevant financial relationships with ineligible companies.

Disclosure: Mohammadreza Azadfard declares no relevant financial relationships with ineligible companies.